The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Vertex Pharmaceuticals (NASDAQ: VRTX) hasn't witnessed the crazy price spike that some other stocks have had in the new bull ...

And both are under priority review. So one is our vanzacaftor triple ... And we intend to fully develop both of these markets at Vertex. We see them both as specialty markets. And longer-term, given ...

A conference call will be held that same day at 9:00 A.M. ET to review the Company's financial results and discuss recent events. HOUSTON, July 17, 2024--Vertex Energy, Inc. (NASDAQ:VTNR ...

Design My Trip’ helps travelers plan their trips to Thailand within seconds, supporting the country’s international tourism ...

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Design My Trip' helps travelers plan their trips to Thailand within seconds, supporting the country's international tourism ...

As global markets rebound from recent sell-offs, technology stocks have led the charge, significantly outpacing their value counterparts. With the S&P 500 Index recovering from its steepest decline ...

Picking a growth stock that becomes a big winner over a decade or more can transform any investor’s returns. I know this from ...

Vertex Pharma has said it will use a priority review voucher (PRV) to speed up the FDA review of its new once-daily triple therapy for cystic fibrosis, which has just hit all its objectives in a ...

An innovative approach to healthcare, precision medicine is a new medical model that takes into account individual ...